Most importantly, the licence will allow Champalimaud’s Comprehensive Cellular Therapy Centre (CCTC), a state-of-the-art medical and scientific institution, to continue the first clinical study with the PD-1/4-1BB construct in patients with solid tumours. This study was originally prepared by Medigene and had already been approved.
The licence…
As part of the German Biotech Days 2026 in Leipzig, the Council of BioRegions in Germany once again presented its prestigious Innovation Award on 21 April. This award recognizes innovative, patented or patent-pending ideas from biotechnology research that promise practical implementation and significant economic potential.
Among the three prize…
Most recently, Sunčana worked as Senior Business Development Manager at Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) for cell and gene therapies. She supported the management with market and competitive analyses as well as technology assessments and was responsible for client acquisition. Prior to…
For the third year running, the annual meeting of the GO-Bio initial (GBI) projects from Ascenion’s Life Science Digital Hub took place as a networking event. Funded by the BMFTR, all managers of projects in the feasibility and exploratory phases collaborating with Ascenion were granted free entry to BioVaria’s two-day lecture programme and the…
The 18th BioVaria brought a record 360 participants from across the international life-science community to Munich. As Europe's leading platform for commercially promising academic innovations, BioVaria connects researchers, entrepreneurs, investors, and industry partners - accelerating the path from discovery to application.
Ascenion,…
This year’s hot topics include novel approaches in the fields of oncology, pharmaceutical research and immunology. In addition, exciting projects relating to infectious diseases and neurological disorders will be presented. Ascenion’s partners are contributing a total of ten projects:A1 ASO-Based mRNA Silencing Technology for PhageHelmholtz…
Ensoma, a US-based in vivo cellular engineering company developing therapies with a one-time treatment regimen, has recently dosed the first patient in its Phase I/II clinical trial of EN-374. The Phase I/II study, carried out in the US, is an open-label, multicentre clinical trial evaluating the safety, tolerability, pharmacodynamics and…
Circular RNAs represent a biologically distinct and highly stable class of RNA molecules. They are enriched in brain tissue, resistant to degradation in blood, and increasingly shown to be implicated in the molecular biology of neurodegenerative diseases. These characteristics make circular RNAs particularly well suited for diagnostic applications…
The PMD-OPTION study enrolled a total of 29 PMD patients across nine expert sites in Germany, Italy and The Netherlands. Its results demonstrate OMT-28’s therapeutic potential to improve the physical condition in PMD based on significant recovery of impaired mitochondrial fitness in the responding patients. The study further underscored the…
There was a lot going on in our otherwise rather quiet offices in Munich-Schwabing! Ascenion’s 15th Knowledge and Technology Transfer Workshop took place on 21–22 January. This year’s agenda once again featured exciting topics at the cutting edge: the latest on the unitary patent, insights into venture builders, and important regulations for AI…
